Literature DB >> 25042200

Exploiting interleukin 6 in multicentric Castleman's disease.

Mark Bower1, Justin Stebbing2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25042200     DOI： 10.1016/S1470-2045(14)70333-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

1.  Focal segmental glomerulosclerosis associated with cutaneous and systemic plasmacytosis.

Authors:  Shinsuke Isobe; Naro Ohashi; Naoko Katahashi; Sayaka Ishigaki; Naoko Tsuji; Takayuki Tsuji; Akihiko Kato; Yoshihide Fujigaki; Akira Shimizu; Hideo Yasuda
Journal:  CEN Case Rep       Date:  2017-09-22

Review 2.  Clinical development of siltuximab.

Authors:  Christine C Davis; Katherine S Shah; Mary Jo Lechowicz
Journal:  Curr Oncol Rep       Date:  2015-07       Impact factor: 5.945

3.  Unicentric Castleman's disease presenting as a pulmonary mass: a diagnostic dilemma.

Authors:  Badi Rawashdeh; Mark Meyer; Dong Yimin; Colon Anthony; Duy Nguyn; Mohammad Moslemi; Simin Golestani; Sobonya Richard; Samuel Kim
Journal:  Am J Case Rep       Date:  2015-04-30

Review 4.  Siltuximab (CNTO 328): a promising option for human malignancies.

Authors:  Runzhe Chen; Baoan Chen
Journal:  Drug Des Devel Ther       Date:  2015-07-02       Impact factor: 4.162

Review 5.  A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab.

Authors:  Lucinda Villaescusa; Francisco Zaragozá; Irene Gayo-Abeleira; Cristina Zaragozá
Journal:  Adv Ther       Date:  2022-01-24       Impact factor: 3.845
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.